SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — May 19, 2017
AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: May 19, 2017 · CIK: 0000946644 · Accession: 0001493152-17-005638
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217671
Letter
Division of Corporation Finance Securities and Exchange Commission (SEC filing No. 333-217671) Acceleration Request Requested Date: May 23, 2017 Requested Time: 4:00 P.M. Eastern Time
Dear Ms. Hayes:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-217671) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Silverman Shin & Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170.
Very
truly yours,
HEMISPHERX
BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
HEMISPHERX
BIOPHARMA, INC.
1617
JFK Boulevard
Philadelphia,
Pennsylvania 19103
May
19, 2017
Suzanne
Hayes, Esq.
Assistant
Director
Division
of Corporation Finance
Securities
and Exchange Commission
100
F Street, NE
Washington,
DC 20002
Re:
Hemispherx
Biopharma, Inc.
Registration
Statement on Form S-1
(SEC
filing No. 333-217671)
Acceleration
Request
Requested
Date: May 23, 2017
Requested
Time: 4:00 P.M. Eastern Time
Dear
Ms. Hayes:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests
that the above-referenced Registration Statement on Form S-1 (File No. 333-217671) (the “Registration Statement”)
be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time
as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the
Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event
with our counsel, Silverman Shin & Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170.
Very
truly yours,
HEMISPHERX
BIOPHARMA, INC.
By:
/s/Adam
Pascale
Adam
Pascale,
Chief
Financial Officer
cc:
Richard Feiner, Esq.